COX-2 and beyond: Approaches to prostaglandin inhibition in human disease (Q34282832)

1 August 2017

1 reference

title

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease (English)

1 reference

1 August 2017

Garret A FitzGerald

1

1 reference

1 August 2017

publication date

1 November 2003

1 reference

Nature Reviews Drug Discovery

1 August 2017

published in

1 reference

1 August 2017

volume

2

1 reference

1 August 2017

issue

11

1 reference

1 August 2017

page(s)

879-890

1 reference

Cyclooxygenases: structural, cellular, and molecular biology

1 August 2017

cites work

1 reference

The productive conformation of arachidonic acid bound to prostaglandin synthase

31 March 2020

1 reference

The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs

31 March 2020

1 reference

31 March 2020

Prostaglandin transport

1 reference

Prostaglandin F(2alpha) receptor-dependent regulation of prostaglandin transport.

31 March 2020

1 reference

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

31 March 2020

1 reference

Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma

31 March 2020

1 reference

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

31 March 2020

1 reference

cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase

31 March 2020

1 reference

Developmental expression of functional cyclooxygenases in zebrafish.

31 March 2020

1 reference

Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation

31 March 2020

1 reference

Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids

31 March 2020

1 reference

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

31 March 2020

1 reference

The coxibs, selective inhibitors of cyclooxygenase-2.

31 March 2020

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

31 March 2020

1 reference

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

31 March 2020

1 reference

31 March 2020

1 reference

Parsing an enigma: the pharmacodynamics of aspirin resistance

31 March 2020

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

31 March 2020

1 reference

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

31 March 2020

1 reference

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

31 March 2020

1 reference

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

31 March 2020

1 reference

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

31 March 2020

1 reference

Biomedicine. Back to an aspirin a day?

31 March 2020

1 reference

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

31 March 2020

1 reference

Platelet activation in unstable coronary disease

31 March 2020

1 reference

Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.

31 March 2020

1 reference

Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis

31 March 2020

1 reference

Role of prostacyclin in the cardiovascular response to thromboxane A2

31 March 2020

1 reference

Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin

31 March 2020

1 reference

Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation

31 March 2020

1 reference

Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics

31 March 2020

1 reference

Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor

31 March 2020

1 reference

Angiotensin II/prostaglandin I2 interactions in spontaneously hypertensive rats.

31 March 2020

1 reference

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

31 March 2020

1 reference

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

31 March 2020

1 reference

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

31 March 2020

1 reference

Relative risk of cardiovascular events in patients with rheumatoid arthritis

31 March 2020

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

31 March 2020

1 reference

The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors

31 March 2020

1 reference

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

31 March 2020

1 reference

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

31 March 2020

1 reference

Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass

31 March 2020

1 reference

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

31 March 2020

1 reference

Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis

31 March 2020

1 reference

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

31 March 2020

1 reference

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

31 March 2020

1 reference

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

31 March 2020

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

31 March 2020

1 reference

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

31 March 2020

1 reference

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

31 March 2020

1 reference

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases

31 March 2020

1 reference

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

31 March 2020

1 reference

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

31 March 2020

1 reference

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

31 March 2020

1 reference

Effect of ibuprofen on cardioprotective effect of aspirin

31 March 2020

1 reference

Cyclooxygenase 2 and the kidney

31 March 2020

1 reference

Frequency of analgesic use and risk of hypertension in younger women

31 March 2020

1 reference

The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents

31 March 2020

1 reference

The choreography of cyclooxygenases in the kidney

31 March 2020

1 reference

Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition

31 March 2020

1 reference

Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease

31 March 2020

1 reference

Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo‐controlled dose–response study

31 March 2020

1 reference

TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O(2)(-) and NO.

31 March 2020

1 reference

Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells

31 March 2020

1 reference

Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling

31 March 2020

1 reference

Emerging therapies for pulmonary hypertension: striving for efficacy and safety

31 March 2020

1 reference

Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds

31 March 2020

1 reference

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

31 March 2020

1 reference

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis

31 March 2020

1 reference

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

31 March 2020

1 reference

Selective COX-2 inhibition improves endothelial function in coronary artery disease

31 March 2020

1 reference

Effects of low-dose aspirin on endothelial function in hypertensive patients

31 March 2020

1 reference

Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension

31 March 2020

1 reference

Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina

31 March 2020

1 reference

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

31 March 2020

1 reference

Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice

31 March 2020

1 reference

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

31 March 2020

1 reference

No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice

31 March 2020

1 reference

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

31 March 2020

1 reference

Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor

31 March 2020

1 reference

The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

31 March 2020

1 reference

Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2

31 March 2020

1 reference

Mechanism of cyclooxygenase-2 upregulation in late preconditioning

31 March 2020

1 reference

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

31 March 2020

1 reference

Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors

31 March 2020

1 reference

Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure

31 March 2020

1 reference

COX-2–Dependent Cardiac Failure in Gh/tTG Transgenic Mice

31 March 2020

1 reference

The relationship between cyclooxygenase-2 expression and colorectal cancer.

31 March 2020

1 reference

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

31 March 2020

1 reference

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

31 March 2020

1 reference

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

31 March 2020

1 reference

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

31 March 2020

1 reference

Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

31 March 2020

1 reference

Inferior collicular seizure generalization produces site-selective cortical induction of cyclooxygenase 2 (COX-2)

31 March 2020

1 reference

Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.

31 March 2020

1 reference

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

31 March 2020

1 reference

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

31 March 2020

1 reference

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

31 March 2020

1 reference

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile

31 March 2020

1 reference

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

31 March 2020

1 reference

Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase

31 March 2020

1 reference

Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model

31 March 2020

1 reference

Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2.

31 March 2020

1 reference

Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis

31 March 2020

1 reference

Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells

31 March 2020

1 reference

Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy

31 March 2020

1 reference

Genetic and pharmacological analysis of prostanoid receptor function

31 March 2020

1 reference

Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema

31 March 2020

1 reference

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

31 March 2020

1 reference

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1225

1 reference

Dimensions Publication ID

1 August 2017

1052083851

0 references

1 reference